169 related articles for article (PubMed ID: 15140572)
1. Functional analysis of Cobra Venom Factor/human C3 chimeras transiently expressed in mammalian cells.
Kölln J; Matzas M; Jänner N; Mix T; Klensang K; Bredehorst R; Spillner E
Mol Immunol; 2004 May; 41(1):19-28. PubMed ID: 15140572
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.
Fritzinger DC; Hew BE; Thorne M; Pangburn MK; Janssen BJ; Gros P; Vogel CW
Dev Comp Immunol; 2009; 33(1):105-16. PubMed ID: 18760301
[TBL] [Abstract][Full Text] [Related]
3. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
[TBL] [Abstract][Full Text] [Related]
4. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
[TBL] [Abstract][Full Text] [Related]
5. Recombinant cobra venom factor.
Vogel CW; Fritzinger DC; Hew BE; Thorne M; Bammert H
Mol Immunol; 2004 Jun; 41(2-3):191-9. PubMed ID: 15159065
[TBL] [Abstract][Full Text] [Related]
6. Molecular isoforms of cobra venom factor-like proteins in the venom of Austrelaps superbus.
Rehana S; Manjunatha Kini R
Toxicon; 2007 Jul; 50(1):32-52. PubMed ID: 17412383
[TBL] [Abstract][Full Text] [Related]
7. Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion.
Vogel CW; Fritzinger DC
Toxicon; 2010 Dec; 56(7):1198-222. PubMed ID: 20417224
[TBL] [Abstract][Full Text] [Related]
8. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
[TBL] [Abstract][Full Text] [Related]
9. Absence of a neutralizing antibody response to humanized cobra venom factor in mice.
Ing M; Hew BE; Fritzinger DC; Delignat S; Lacroix-Desmazes S; Vogel CW; Rayes J
Mol Immunol; 2018 May; 97():1-7. PubMed ID: 29525557
[TBL] [Abstract][Full Text] [Related]
10. Purification of native and recombinant cobra venom factor using thiophilic adsorption chromatography.
Kölln J; Braren I; Bredehorst R; Spillner E
Protein Pept Lett; 2007; 14(5):475-80. PubMed ID: 17584174
[TBL] [Abstract][Full Text] [Related]
11. Cancer research center hotline: complement depletion: use of human C3/cobra venom factor (CVF) chimeric proteins as therapeutic agents.
Fritzinger DC
Hawaii Med J; 2005 May; 64(5):133-4, 137. PubMed ID: 15989147
[No Abstract] [Full Text] [Related]
12. Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases.
Vogel CW; Fritzinger DC; Gorsuch WB; Stahl GL
Thromb Haemost; 2015 Mar; 113(3):548-52. PubMed ID: 25031089
[TBL] [Abstract][Full Text] [Related]
13. Preparation of complement fragments C3b and C3a from purified rat complement component C3 by activated cobra venom factor.
Usami M; Ohno Y
J Pharmacol Toxicol Methods; 2005; 52(2):260-3. PubMed ID: 16125624
[TBL] [Abstract][Full Text] [Related]
14. Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents.
Fritzinger DC; Hew BE; Lee JQ; Newhouse J; Alam M; Ciallella JR; Bowers M; Gorsuch WB; Guikema BJ; Stahl GL; Vogel CW
Adv Exp Med Biol; 2008; 632():293-307. PubMed ID: 19025130
[TBL] [Abstract][Full Text] [Related]
15. Structure and function of recombinant cobra venom factor.
Kock MA; Hew BE; Bammert H; Fritzinger DC; Vogel CW
J Biol Chem; 2004 Jul; 279(29):30836-43. PubMed ID: 15131128
[TBL] [Abstract][Full Text] [Related]
16. Humanized cobra venom factor: structure, activity, and therapeutic efficacy in preclinical disease models.
Vogel CW; Finnegan PW; Fritzinger DC
Mol Immunol; 2014 Oct; 61(2):191-203. PubMed ID: 25062833
[TBL] [Abstract][Full Text] [Related]
17. Primary structure of cobra complement component C3.
Fritzinger DC; Petrella EC; Connelly MB; Bredehorst R; Vogel CW
J Immunol; 1992 Dec; 149(11):3554-62. PubMed ID: 1431125
[TBL] [Abstract][Full Text] [Related]
18. Molecular cloning and derived primary structure of cobra venom factor.
Fritzinger DC; Bredehorst R; Vogel CW
Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12775-9. PubMed ID: 7809120
[TBL] [Abstract][Full Text] [Related]
19. Molecular cloning and characterization of a complement-depleting factor from king cobra, Ophiophagus hannah.
Zeng L; Sun QY; Jin Y; Zhang Y; Lee WH; Zhang Y
Toxicon; 2012 Sep; 60(3):290-301. PubMed ID: 22561424
[TBL] [Abstract][Full Text] [Related]
20. Antigenic relationships between human and cobra complement factors C3 and cobra venom factor (CVF) from the Indian cobra (Naja naja).
Eggertsen G; Lundwall A; Hellman U; Sjöquist J
J Immunol; 1983 Oct; 131(4):1920-3. PubMed ID: 6194220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
